Sinopharm's 2nd gen protein subunit vaccine NVSI-06-08 just got approved for clinical trials in China. It already has EUA in UAE with local phase III trial ongoing. According to Sinopharm, 80m doses has already been produced with 20m delivered to international buyers.
Since HK data for 3 doses Sinovac looks pretty solid I don't think there's a hurry for new vaccines. Let people finish the real-world proven 3 doses inactivated vaccines. New vaccines can wait for the 4th shot.
Junshi's VV116 remdesivir-like oral anti-viral pill has begun phase II/III trial in Shanghai and phase II trial in Beijing. I don't expect VV116 to be as good as Paxlovid, but it should be extremely easy to scale up production.
Junshi's VV993, a 3C-like protease inhibitor similar to the main component of Paxlovid, is in pre-clinical. There are 3 other 3C-like protease inhibitors under development in China, all in pre-clinical.
Once VV116 is ready China should announce an open-up target date and pressure people to get vaccinated. Given limited medical resource I see no problem for China to set an upper limit for ICU beds for covid-19 patients and deprioritize people who are unvaccinated without good medical reasons. I have no problem with deprioritizing liver transplants for alcoholics, so I see no ethical problem here.